VAM 2023: Baroreflex Activation Therapy - A Novel Extravascular Procedure for Heart Failure by Dr. R. Clement Darling and Dr. Manuel Perez-Izquierdo
Dr. R. Clement Darling discusses his experience implanting 17+ patients with Barostim...
VAM 2023: Baroreflex Activation Therapy - A Novel Extravascular Procedure for Heart Failure by Dr. Manuel Perez-Izquierdo
VAM 2023: Dr. R. Clement Darling and Dr. Manuel Perez-Izquierdo Discussion
Dr. R. Clement Darling and Dr. Manuel Perez-Izquierdo Discussio and Q&A from VAM 2023
What is the unmet need for new treatments for heart failure with reduced ejection fraction?
Patient with Dyspnea and Normal Ejection Fraction: Heart Failure with Preserved Ejection Fraction - Steven J. Lester
Treatment of Worsening Heart Failure in Asia Pacific
Chris Gale - Abstract Heart Podcast Ep.2 - Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction with Professor Mark Petrie
Paper available here: Dapagliflozin in Patients with Heart Failure and Reduced...
Chris Gale - Abstract Heart Podcast Ep.2 - Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction with Professor Mark Petrie
Paper available here: Dapagliflozin in Patients with Heart Failure and Reduced...
Baroreflex Activation Therapy (BAT): An Effective Therapy for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
Chris Gale - Abstract Heart Podcast Ep.4 - Dapagliflozin in Patients with Chronic Kidney Disease with Professor David Wheeler
Paper available here: Dapagliflozin in Patients with Chronic Kidney Disease with...
Chris Gale - Abstract Heart Podcast Ep.4 - Dapagliflozin in Patients with Chronic Kidney Disease with Professor David Wheeler
Paper available here: Dapagliflozin in Patients with Chronic Kidney Disease with...
Refractory Heart Failure With Normal Ejection Fraction: Constriction - Jae K. Oh
Where do you see Barostim fitting into management of heart failure patients?
Refractory Heart Failure With Normal Ejection Fraction: Restrictive Cardiomyopathy - Bonita Anderson
Consideration for using Barostim in Patients with Advanced Systolic Heart Failure
How to Select Patients who Could Benefit from Barostim
How do you identify ideal patients for Barostim?
CSI FOCUS D-HF: NEUROMODULATION IN THE MANAGEMENT OF HEART FAILURE AND ITS COMORBIDITIES: DIABETES, SLEEP APNEA AND HYPERTENSION
The MDT discussion – defining standards
How Dapagliflozin is exerting serendipitous effect in DAPA-HF trial in Heart Failure?
